2/9
07:20 am
imvt
Immunovant (NASDAQ:IMVT) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Immunovant (NASDAQ:IMVT) had its "buy" rating reaffirmed by analysts at Guggenheim.
2/7
12:33 pm
imvt
A Look At Immunovant (IMVT) Valuation After Trial Progress Updates And Extended Cash Runway [Yahoo! Finance]
Low
Report
A Look At Immunovant (IMVT) Valuation After Trial Progress Updates And Extended Cash Runway [Yahoo! Finance]
2/6
10:36 am
imvt
Immunovant Q3 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Immunovant Q3 Earnings Call Highlights [Yahoo! Finance]
2/6
07:05 am
imvt
Immunovant GAAP EPS of -$0.61 beats by $0.10 [Seeking Alpha]
Medium
Report
Immunovant GAAP EPS of -$0.61 beats by $0.10 [Seeking Alpha]
2/6
07:00 am
imvt
Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025
Medium
Report
Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025
1/23
05:25 pm
imvt
Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
Low
Report
Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
1/13
04:05 am
imvt
Immunovant (NASDAQ:IMVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Immunovant (NASDAQ:IMVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/12
10:33 am
imvt
Truist Lifts Immunovant (IMVT) PT to $22 on Updated 2026 Financial Modeling [Yahoo! Finance]
Low
Report
Truist Lifts Immunovant (IMVT) PT to $22 on Updated 2026 Financial Modeling [Yahoo! Finance]
1/8
12:20 pm
imvt
Immunovant (NASDAQ:IMVT) had its price target raised by analysts at Truist Financial Corporation from $16.00 to $22.00. They now have a "hold" rating on the stock.
Low
Report
Immunovant (NASDAQ:IMVT) had its price target raised by analysts at Truist Financial Corporation from $16.00 to $22.00. They now have a "hold" rating on the stock.
1/6
08:02 am
imvt
Immunovant (NASDAQ:IMVT) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating.
Medium
Report
Immunovant (NASDAQ:IMVT) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating.
1/5
12:00 pm
imvt
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)
Low
Report
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)
12/18
09:09 am
imvt
Immunovant (NASDAQ:IMVT) had its "buy" rating reaffirmed by analysts at Guggenheim.
Medium
Report
Immunovant (NASDAQ:IMVT) had its "buy" rating reaffirmed by analysts at Guggenheim.
12/15
12:58 pm
imvt
Immunovant (NASDAQ:IMVT) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $18.00 to $28.00. They now have a "neutral" rating on the stock.
Low
Report
Immunovant (NASDAQ:IMVT) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $18.00 to $28.00. They now have a "neutral" rating on the stock.
12/12
06:13 pm
imvt
Roivant Sciences Ltd. (ROIV) Analyst/Investor Day Transcript [Seeking Alpha]
Medium
Report
Roivant Sciences Ltd. (ROIV) Analyst/Investor Day Transcript [Seeking Alpha]
12/12
04:30 pm
imvt
Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement [Seeking Alpha]
Low
Report
Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement [Seeking Alpha]
12/11
08:06 am
imvt
Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor Day [Yahoo! Finance]
High
Report
Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor Day [Yahoo! Finance]
12/11
01:29 am
imvt
Immunovant Announces Pricing of $550 Million Common Stock Financing
Medium
Report
Immunovant Announces Pricing of $550 Million Common Stock Financing
12/10
01:22 pm
imvt
Immunovant (IMVT) Down 0.6% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]
Medium
Report
Immunovant (IMVT) Down 0.6% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]
11/29
01:39 pm
imvt
Oppenheimer Maintains Outperform Rating on Immunovant (IMVT) Following Q2 2026 Earnings [Yahoo! Finance]
Medium
Report
Oppenheimer Maintains Outperform Rating on Immunovant (IMVT) Following Q2 2026 Earnings [Yahoo! Finance]